Max Healthcare to introduce 24×7 ward monitoring system

New Delhi, To bring Intensive Care Unit (ICU)-standard monitoring across general wards, Max Healthcare on Wednesday announced a partnership with US-based medical technology company Vios Medical to launch a continuous vital monitoring system built on a medical-grade Internet of Things (IoT) framework.

The technology provides continuous monitoring of vital signs such as oxygen saturation, heart rate, respiratory rate, electrocardiogram (ECG) and blood pressure in general wards, thereby enabling early detection and critical care facility even outside an ICU set-up.

The VIOS ward monitoring system comprises two connected sensors — chest and finger — which communicate wirelessly (via Bluetooth) with a bed-side tablet that maps all vital trends.

These, along with alarms (in case of adverse episodes/ change in trends), can be remotely viewed by nursing staff and clinicians at nursing stations and smartphones via web links.

This ensures that hospital staff can continuously monitor even the patients who are in rooms and ensure better care, Max Healthcare said in a statement.

“The psychosis/anxiety felt by patients under long term critical care has a strong impact on their recovery. With this technology solution, patients can experience 24×7 critical monitoring, even outside an ICU environment, helping them recover in the comfortable presence of loved ones,” said Sandeep Budhiraja, Clinical Director at Max Healthcare.

The technology also aids clinicians in making more effective treatment plans by providing vital trends and patterns, the statement added.

A successful pilot of the system, covering several specialties such as Cardiology, Pulmonology, Medicine and Neurology was conducted at Max Healthcare, Dehradun.

The system, which has the potential to reduce up to 30 per cent critical care costs as compared to ICU charges, will be launched soon across all network hospitals under Max Healthcare, the statement added.

  • Related Posts

    Alembic Pharma Gets USFDA Nod for Dapagliflozin

    New Delhi: Alembic Pharmaceuticals Ltd on Tuesday said it has received final approval from the US health regulator for its generic version of dapagliflozin tablets used to control blood sugar…

    Aurobindo Pharma Board approves ₹800 cr share buyback plan

    Generic drugmaker is proposing to buyback more than 54.23 lakh equity shares at ₹1,475 each, fixes April 17, 2026 as the record date Aurobindo Pharma’s Board has approved the generic…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Alembic Pharma Gets USFDA Nod for Dapagliflozin

    Alembic Pharma Gets USFDA Nod for Dapagliflozin

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    On World Health Day ‘CAHO Na Patient Se Pyaar Hai’

    Supreme Court willing to understand Angst of Doctors regarding Consumer Protection Act

    Supreme Court willing to understand Angst of Doctors regarding Consumer Protection Act

    Aurobindo Pharma Board approves ₹800 cr share buyback plan

    Aurobindo Pharma Board approves ₹800 cr share buyback plan

    Three held for cheating SCB Hospital patients on promise of arranging blood

    Three held for cheating SCB Hospital patients on promise of arranging blood

    NATHEALTH resolves to evolve to fit The Bill of Viksit Bharat

    NATHEALTH   resolves to evolve to fit The Bill of Viksit Bharat